Your browser doesn't support javascript.
loading
تبين: 20 | 50 | 100
النتائج 1 - 1 de 1
المحددات
إضافة المرشحات








النطاق السنوي
1.
مقالة ي الانجليزية | WPRIM | ID: wpr-1010589

الملخص

Oral squamous cell carcinoma (OSCC) is a prevalent malignant tumor affecting the head and neck region (Leemans et al., 2018). It is often diagnosed at a later stage, leading to a poor prognosis (Muzaffar et al., 2021; Li et al., 2023). Despite advances in OSCC treatment, the overall 5-year survival rate of OSCC patients remains alarmingly low, falling below 50% (Jehn et al., 2019; Johnson et al., 2020). According to statistics, only 50% of patients with oral cancer can be treated with surgery. Once discovered, it is more frequently at an advanced stage. In addition, owing to the aggressively invasive and metastatic characteristics of OSCC, most patients die within one year of diagnosis. Hence, the pursuit of novel therapeutic drugs and treatments to improve the response of oral cancer to medication, along with a deeper understanding of their effects, remains crucial objectives in oral cancer research (Johnson et al., 2020; Bhat et al., 2021; Chen et al., 2023; Ruffin et al., 2023).


الموضوعات
Humans , Mouth Neoplasms/pathology , Carcinoma, Squamous Cell/metabolism , Luteolin/therapeutic use , Squamous Cell Carcinoma of Head and Neck/drug therapy , Head and Neck Neoplasms/drug therapy , Cell Line, Tumor
اختيار الاستشهادات
تفاصيل البحث